Lilly’s Solanezumab Reaches End Of Road As Donanemab Stays On Development Path

Last Study Of Soluble Amyloid-Clearing Antibody Fails

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.